Significant Reduction in Side Effects Is Major Appeal

Willis-Knighton urologist, Tom Siskron, IV, MD, has performed the first Aquablation® therapy procedure in the state of Louisiana at Willis-Knighton Medical Center.  Aquablation is a minimally invasive robotic treatment for patients with benign prostatic hyperplasia (BPH) or enlarged prostate.  The patient, who was treated on July 17, is now enjoying relief from BPH. Dr. Siskron practices at Signature Urology, which is part of the Willis-Knighton Physician Network.

This procedure uses a heat-free waterjet controlled by robotic technology to surgically remove obstructive prostate tissue and provide long lasting symptom relief. It offers significant improvements in time, safety and reduced. One of its greatest benefits is the reduction of potential complications and long-term side effects.

“Aquablation is an exciting new technology that will improve the efficacy and safety of the traditional gold standard treatment for BPH, which is the TURP (transurethral resection of the prostate),” Dr. Siskron said. “I haven’t been more excited about something used while helping my patients in the management of their  urologic issues since the daVinci robot was introduced 20 years ago.”

One in two men ages 51 to 60 have BPH. It is one of the most common urological conditions seen by urologists. An enlarged prostate is a noncancerous condition that produces many symptoms, including loss of bladder control, urgency, frequency, slow stream, straining, incomplete emptying and hesitancy in urination. Aquablation therapy offers relief from these symptoms.

The purchase of the Aquablation equipment reinforces Willis-Knighton’s commitment to providing leading edge technology to patients from throughout the Ark-La-Tex.